Biotech Values

[mcbio]

Regardless I see ENTA a great value here since Abbvie seems totally committed and there is very little chance they won't be approved

I'm of the opinion that it's not simply a question of approval but rather you need to have confidence that ABBV/ENTA combo will be able to effectively compete against both GILD and the future QD IFN/ribavirin-free HCV DAA combos containing fewer components. If this turns out to be true, then, sure, I think ENTA will prove to be a great value here. But, I think the market is assigning some doubt on this front (I am as well) and that's why you see the cheap valuation.